Hello, Welcome to Shine Consultant !
Summit & Event Shine Speaker Bureau Shine Advisor Shine Event Service
  • Summit & Event :
    With field research of markets and industries which is analyzed from a global strategic perspective by our professional teams, as well as hot topics which interest leadership and management, Shine Consultant provides you with one-stop platform of dialogue, practice -sharing and social network!
  • Shine Speaker Bureau:
    Committed to provide keynote speakers, executive learning masterclasses and boardroom advisory for global enterprises and institutions, each service provides a deeper and more interactive experience, especially for small, selected audiences and key individuals. We have the resources of the most influential business leaders and experts, who are the most outstanding representatives in their fields. Our team consists of experienced speech and event managers, and we focus on building long-term and in-depth partnerships.
  • Shine Advisor:
    As world-class insight network, we connects clients-decision makers with vetted subject matter experts-advisors. Our clients leverage the insights and perspectives shared by our advisors to stay informed and make better business decisions.We have over 600,000 Shine Advisors in 20 industries, which continues to grow every day.
  • Shine Event Service:
    Committed to be the world's most professional provider of industrial Summit & Event. We provide one-stop professional services, including investigating and planning, on-demand inviting, marketing and promoting, operating, project management, live& digital conference, each service is performed by an experienced professional team matched with long-term industrial resources. We focus on establishing long-term and in-depth partnerships.
Guest Information

Chief Business Development Officer


SciClone Pharmaceuticals co., LTD

Dr. Zhu has more than 20 years of experience in the pharmaceutical industry and worked with both global pharmaceutical companies (Pfizer and JNJ) and Chinese pharmaceutical company. He has done 28 strategic transactions (total value > US$3 billion) including the 2 recent landmark deals in China, the Joint Venture agreement between Amgen and Betta Pharma to commercialize Amgen’s Vectibix® (panitumumab) in China for colorectal cancer patients in May 2013, and the US$20 million strategic investment in Xcovery by Betta Pharma and acquired the China right of Ensartinib in October 2014.